Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 3/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | CPT1A | P50416 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.35 |
| ▸ | CFB | P00751 | 2/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205260 | 0.76 | HTT (0.42) | OPRM1OPRD1OPRK1CPT1ARIPK1 | |
| SCHEMBL4968626 | 0.76 | CFB (0.47) | GRM5RIPK1CFBCCNCCDK8 | |
| SCHEMBL4968612 | 0.76 | CFB (0.47) | GRM5RIPK1CFBCCNCCDK8 | |
| SCHEMBL4966459 | 0.72 | ALDH1A1 (0.43) | PARP14PARP10RIPK1HTT | |
| SCHEMBL4965759 | 0.71 | RIPK1 (0.43) | RIPK1CFBHTTHSP90AA1HSP90AB1 | |
| SCHEMBL26693398 | 0.71 | PARP14 (0.57) | PARP14PARP10CPT1ARIPK1CPT2 | |
| SCHEMBL4964480 | 0.69 | RIPK1 (0.41) | PARP14PARP10RIPK1CCNCCDK8 | |
| SCHEMBL6246105 | 0.69 | RIPK1 (0.66) | PARP14PARP10GRM5RIPK1HSP90AA1 | |
| SCHEMBL26985110 | 0.68 | RIPK1 (0.41) | GRM5RIPK1CFBCCNCCDK8 | |
| SCHEMBL27128622 | 0.68 | RIPK1 (0.41) | GRM5RIPK1CFBCCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296235-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2014-10-02 | — | — | US | disclosed |
| US-8697736-B2 | 1H-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent PARP inhibitors | ABBVIE INC. (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2012038751-A3 | PROCESS FOR THE PURIFICATION OF AROMATIC DICARBOXYLIC ACID | DAVY PROCESS TECHNOLOGY LIMITED (GB) | 2012-05-10 | — | — | WO | disclosed |
| EP-1957477-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20070179136-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296235-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | PARP14 9/4885PARP10 13/4885OPRM1 3118/4885 |
| US-20070179136-A1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | PARP14 9/4885PARP10 13/4885OPRM1 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.